These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 22665137

  • 1. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
    Porter WD, Flatt PR, Hölscher C, Gault VA.
    Int J Obes (Lond); 2013 May; 37(5):678-84. PubMed ID: 22665137
    [Abstract] [Full Text] [Related]

  • 2. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA.
    Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
    [Abstract] [Full Text] [Related]

  • 3. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
    Porter D, Faivre E, Flatt PR, Hölscher C, Gault VA.
    Peptides; 2012 May; 35(1):1-8. PubMed ID: 22465882
    [Abstract] [Full Text] [Related]

  • 4. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA, Kerr BD, Harriott P, Flatt PR.
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [Abstract] [Full Text] [Related]

  • 5. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 6. Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
    Chen LN, Lyu J, Yang XF, Ji WJ, Yuan BX, Chen MX, Ma X, Wang B.
    Int J Mol Med; 2013 Oct; 32(4):892-900. PubMed ID: 23877319
    [Abstract] [Full Text] [Related]

  • 7. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [Abstract] [Full Text] [Related]

  • 8. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY, Kim YW, Oh H, Choi CS, Ahn JH, Lee BW, Kang ES, Cha BS, Lee HC.
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [Abstract] [Full Text] [Related]

  • 9. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
    Pathak NM, Pathak V, Lynch AM, Irwin N, Gault VA, Flatt PR.
    Mol Cell Endocrinol; 2015 Sep 05; 412():95-103. PubMed ID: 26048772
    [Abstract] [Full Text] [Related]

  • 10. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
    Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M.
    Circulation; 2013 Jan 01; 127(1):74-85. PubMed ID: 23186644
    [Abstract] [Full Text] [Related]

  • 11. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet.
    Gault VA, Porter WD, Flatt PR, Hölscher C.
    Int J Obes (Lond); 2010 Aug 01; 34(8):1341-4. PubMed ID: 20351729
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.
    Lennox R, Porter DW, Flatt PR, Holscher C, Irwin N, Gault VA.
    Neuropharmacology; 2014 Nov 01; 86():22-30. PubMed ID: 24998752
    [Abstract] [Full Text] [Related]

  • 13. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
    O'Harte FP, Franklin ZJ, Irwin N.
    Diabetes Obes Metab; 2014 Dec 01; 16(12):1214-22. PubMed ID: 25060150
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
    McClean PL, Gault VA, Harriott P, Hölscher C.
    Eur J Pharmacol; 2010 Mar 25; 630(1-3):158-62. PubMed ID: 20035739
    [Abstract] [Full Text] [Related]

  • 15. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
    Kerr BD, Flatt PR, Gault VA.
    Biochem Pharmacol; 2010 Aug 01; 80(3):396-401. PubMed ID: 20417187
    [Abstract] [Full Text] [Related]

  • 16. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N, Montgomery IA, Moffett RC, Flatt PR.
    Biochem Pharmacol; 2013 Jan 01; 85(1):81-91. PubMed ID: 23085436
    [Abstract] [Full Text] [Related]

  • 17. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
    Lennox R, Porter DW, Flatt PR, Gault VA.
    ChemMedChem; 2013 Apr 01; 8(4):595-602. PubMed ID: 23138973
    [Abstract] [Full Text] [Related]

  • 18. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
    Tomas E, Wood JA, Stanojevic V, Habener JF.
    Regul Pept; 2011 Aug 08; 169(1-3):43-8. PubMed ID: 21549160
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ.
    Gastroenterology; 2010 Sep 08; 139(3):857-68. PubMed ID: 20546737
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 08; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.